It is aimed to evaluate FAP expression and its success in predicting treatment response before immunotherapy used in the treatment of malignant mesothelioma with Ga68 FAPI PET/CT imaging, which allows in vivo evaluation of FAP expression, which is thought to be associated with immunosuppression and resistance to immunotherapy.
Patients diagnosed with pleural mesothelioma and planned for immunotherapy will be included in the study. Patients will undergo Ga68 FAPI PET/CT imaging within 10 days before the start of immunotherapy treatment, and SUVmax, SUVmean, metabolic tumor volume and total Ga68 FAPI uptake parameters will be obtained from the tumors. Following this, the routine treatment and follow-up of the patients will be carried out by their clinicians. It will be evaluated whether there is a correlation between treatment response and initial Ga-68 FAPI PET findings.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
30
imaging of FAP expression of tumor before immunotherapy
Ankara University School of Medicine
Ankara, Turkey (Türkiye)
RECRUITINGPrediction of immune therapy response with Ga-68 FAPI PET
prediction of immunotherapy response with SUVmax measured with Ga-68 FAPI PET before immunotherapy
Time frame: 6. month after initiation of therapy
Prediction of immune therapy response with Ga-68 FAPI PET
prediction of immunotherapy response with total FAPI volume measured with Ga-68 FAPI PET before immunotherapy
Time frame: 6. month after initiation of therapy
Prediction of immune therapy response with Ga-68 FAPI PET
prediction of immunotherapy response with total lesion FAPI uptake measured with Ga-68 FAPI PET before immunotherapy
Time frame: 6. month after initiation of therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.